Encompass Health (EHC) Stock Forecast & Price Target

Encompass Health is supported by a structurally undersupplied inpatient rehabilitation market, where demand is being lifted by an aging population while facility growth has remained stagnant, creating ample room for discharge and bed-expansion growth. 2Q EBITDA-NCI beat consensus by 3% despite an $11.5 million year-over-year headwind from net SDPs, same-store volume rose 2.8%, and management lifted adjusted EBITDA guidance by $15 million at both ends, reinforcing confidence in execution. The company’s moat is strengthened by higher-acuity case mix, with 3.9% net revenue per discharge growth driven by stroke and brain injury, plus balance-sheet flexibility at 1.9x net leverage and an 89% success rate in its Medicare Advantage admit-and-appeal pilot, which adds incremental upside.

Encompass Health is facing a negative outlook because its earnings power depends on an IRF model that is increasingly exposed to reimbursement compression, regulatory scrutiny, and payor pressure. Although Medicare FFS margins are elevated at 16.1% on average through 2026E and could reach 18% in 2026E, MedPAC’s suggested -7% cut to IRF rates could drive an estimated -18% adj. EBITDA impact, while Medicare Advantage denials and admission pressure may further slow volumes. On top of that, rising maintenance capex toward ~15% of revenue, higher staffing costs, and turnover create margin pressure and may limit cash available for expansion and shareholder returns.